1. Home
  2. YSG vs FATE Comparison

YSG vs FATE Comparison

Compare YSG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yatsen Holding Limited

YSG

Yatsen Holding Limited

N/A

Current Price

$2.03

Market Cap

238.3M

ML Signal

N/A

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

260.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
FATE
Founded
2016
2007
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.3M
260.0M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
YSG
FATE
Price
$2.03
$1.13
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
★ $5.72
AVG Volume (30 Days)
43.4K
★ 1.5M
Earning Date
11-27-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 29.88
EPS
★ N/A
N/A
Revenue
N/A
★ $6,646,000.00
Revenue This Year
$4.74
N/A
Revenue Next Year
$11.48
$18.72
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.67
$0.95
52 Week High
$6.59
$3.23

Technical Indicators

Market Signals
Indicator
YSG
FATE
Relative Strength Index (RSI) 38.36 20.53
Support Level $1.67 $1.07
Resistance Level $3.05 $1.38
Average True Range (ATR) 0.21 0.17
MACD 0.00 -0.08
Stochastic Oscillator 36.42 0.00

Price Performance

Historical Comparison
YSG
FATE

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: